What is N0877 used for?

N0877 is indicated for Type 2 diabetes.

N0877 is developed by Eurofarma Laboratorios S.A..

What are the side effects of N0877?

Common side effects include Nausea, Diarrhea, Vomiting.

Last reviewed 2026-04-23 · How we verify

N0877

Eurofarma Laboratorios S.A. · Phase 3 active Small molecule

N0877 is a small molecule drug that targets the SGLT2 receptor.

N0877 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	N0877
Sponsor	Eurofarma Laboratorios S.A.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, N0877 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results